Athina Soragia Gkazi

Athina Soragia Gkazi

Auto-generated profile, based on publicly available information

Athina Soragia Gkazi

UCL Great Ormond Street Institute of Child Health

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2015 in Science
Verified
Journal Article
Closed access
ECElizabeth T. Cirulli
Elizabeth T. Cirulli
BLBrittany Lasseigne
Brittany Lasseigne
SPSlavé Petrovski
Slavé Petrovski
PSPeter C. Sapp
Peter C. Sapp
PDPatrick A. Dion
Patrick A. Dion
DGDavid B. Goldstein
David B. Goldstein
New players in Lou Gehrig's disease: Amyotrophic lateral sclerosis (ALS), often referred to as “Lou Gehrig's disease,” is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. Cirulli et al. sequenced the expressed genes of nearly 3000 ALS patients and compared them with those of more than 6000 controls (see the Perspective by Singleton and Traynor). They identified several proteins that were linked to disease in patients. One such protein, TBK1, is implicated in innate immunity and autophagy and may represent a therapeutic target. Science , this issue p. 1436 ; see also p. 1422

1 March 2018 in Neuron
Verified
Journal Article
Closed access
ANAude Nicolas
Aude Nicolas
KKKevin P. Kenna
Kevin P. Kenna
ARAlan E. Renton
Alan E. Renton
NTNicola Ticozzi
Nicola Ticozzi
FFFaraz Faghri
Faraz Faghri
NTNatalie A. Twine
Natalie A. Twine

1 October 2014 in Neuron
Verified
Journal Article
Closed access
BSBradley N. Smith
Bradley N. Smith
NTNicola Ticozzi
Nicola Ticozzi
CFClaudia Fallini
Claudia Fallini
AGAthina Soragia Gkazi
Athina Soragia Gkazi
STSimon Topp
Simon Topp
CBCinzia Bertolin
Cinzia Bertolin

26 October 2022 in Science Translational Medicine
Verified
Journal Article
Closed access
GOGiorgio Ottaviano
Giorgio Ottaviano
CGChristos Georgiadis
Christos Georgiadis
SGSoragia Athina Gkazi
Soragia Athina Gkazi
FSFarhatullah Syed
Farhatullah Syed
HZHong Zhan
Hong Zhan
DKDaesik Kim
Daesik Kim
Genome editing of allogeneic T cells can provide “off-the-shelf” alternatives to autologous chimeric antigen receptor (CAR) T cell therapies. Disruption of T cell receptor α chain (TRAC) to prevent graft-versus-host disease (GVHD) and removal of CD52 (cluster of differentiation 52) for a survival advantage in the presence of alemtuzumab have previously been investigated using transcription activator–like effector nuclease (TALEN)-mediated knockout. Here, we deployed next-generation CRISPR-Cas9 editing and linked CAR expression to multiplexed DNA editing of TRAC and CD52 through incorporation of self-duplicating CRISPR guide RNA expression cassettes within the 3’ long terminal repeat of a CAR19 lentiviral vector. Three cell banks of TT52CAR19 T cells were generated and cryopreserved. A phase 1, open-label, non-randomized clinical trial was conducted and treated six children with relapsed/refractory CD19-positive B cell acute lymphoblastic leukemia (B-ALL) (NCT04557436). Lymphodepletion included fludarabine, cyclophosphamide, and alemtuzumab and was followed by a single infusion of 0.8 × 10 6 to 2.0 × 10 6 CAR19 T cells per kilogram with no immediate toxicities. Four of six patients infused with TT52CAR19 T cells exhibited cell expansion, achieved flow cytometric remission, and then proceeded to receive allogeneic stem cell transplantation. Two patients required biological intervention for grade II cytokine release syndrome, one patient developed transient grade IV neurotoxicity, and one patient developed skin GVHD, which resolved after transplant conditioning. Other complications were within expectations, and primary safety objectives were met. This study provides a demonstration of the feasibility, safety, and therapeutic potential of CRISPR-engineered immunotherapy.

15 April 2016 in Nature Communications
Verified
Journal Article
Open access
PDF file
KWKelly L. Williams
Kelly L. Williams
STSimon Topp
Simon Topp
SYShu Yang
Shu Yang
BSBradley Smith
Bradley Smith
JFJennifer A. Fifita
Jennifer A. Fifita
IBIan Blair
Ian Blair
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are overlapping, fatal neurodegenerative disorders in which the molecular and pathogenic basis remains poorly understood. Ubiquitinated protein aggregates, of which TDP-43 is a major component, are a characteristic pathological feature of most ALS and FTD patients. Here we use genome-wide linkage analysis in a large ALS/FTD kindred to identify a novel disease locus on chromosome 16p13.3. Whole-exome sequencing identified aCCNFmissense mutation at this locus. Interrogation of international cohorts identified additional novelCCNFvariants in familial and sporadic ALS and FTD. Enrichment of rare protein-alteringCCNFvariants was evident in a large sporadic ALS replication cohort.CCNFencodes cyclin F, a component of an E3 ubiquitin–protein ligase complex (SCFCyclin F). Expression of mutantCCNFin neuronal cells caused abnormal ubiquitination and accumulation of ubiquitinated proteins, including TDP-43 and a SCFCyclin Fsubstrate. This implicates common mechanisms, linked to protein homeostasis, underlying neuronal degeneration.

25 May 2021 in Leukemia
Verified
Journal Article
Open access
PDF file
CGChristos Georgiadis
Christos Georgiadis
JRJane Rasaiyaah
Jane Rasaiyaah
SGSoragia Athina Gkazi
Soragia Athina Gkazi
RPRoland Preece
Roland Preece
AEAniekan Etuk
Aniekan Etuk
WQWaseem Qasim
Waseem Qasim
Targeting T cell malignancies using chimeric antigen receptor (CAR) T cells is hindered by ‘T v T’ fratricide against shared antigens such as CD3 and CD7. Base editing offers the possibility of seamless disruption of gene expression of problematic antigens through creation of stop codons or elimination of splice sites. We describe the generation of fratricide-resistant T cells by orderly removal of TCR/CD3 and CD7 ahead of lentiviral-mediated expression of CARs specific for CD3 or CD7. Molecular interrogation of base-edited cells confirmed elimination of chromosomal translocations detected in conventional Cas9 treated cells. Interestingly, 3CAR/7CAR co-culture resulted in ‘self-enrichment’ yielding populations 99.6% TCR−/CD3−/CD7−. 3CAR or 7CAR cells were able to exert specific cytotoxicity against leukaemia lines with defined CD3 and/or CD7 expression as well as primary T-ALL cells. Co-cultured 3CAR/7CAR cells exhibited highest cytotoxicity against CD3 + CD7 + T-ALL targets in vitro and an in vivo human:murine chimeric model. While APOBEC editors can reportedly exhibit guide-independent deamination of both DNA and RNA, we found no problematic ‘off-target’ activity or promiscuous base conversion affecting CAR antigen-specific binding regions, which may otherwise redirect T cell specificity. Combinational infusion of fratricide-resistant anti-T CAR T cells may enable enhanced molecular remission ahead of allo-HSCT for T cell malignancies.